

ASX Announcement

Medibio Limited – 20 January 2022



Non-Renounceable Entitlement Offer Cleansing Notice under Section 708AA(2)(F) of the Corporations Act 2001 (Cth)

The Directors of Medibio Limited (ASX: MEB, “**Medibio**” or the “**Company**”) give notice under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Medibio announced on 15 December 2021 it is seeking to raise approximately \$3.4 million (before costs) by way of a partially underwritten for an amount up to \$1 million, Non-Renounceable Entitlement Offer (“**Entitlement Offer**”).

Under the Entitlement Offer, shareholders with a registered address in Australia and New Zealand in which Medibio decided to make offers are invited to subscribe for one (1) fully paid ordinary share (**New Shares**) for every three (3) fully paid ordinary shares held as at 7.00pm (AEDT) on Tuesday, 25 January 2022. Investors subscribing for shares under the Entitlement Offer will also be eligible to receive one (1) free attaching option for every two (2) New Shares issued.

Medibio confirms that:

1. The securities will be offered pursuant to the Entitlement Offer without disclosure under Part 6D.2 of the Corporations Act.
2. This notice is being given under section 708AA(2)(f) of the Corporations Act.
3. As at the date of this notice, Medibio has complied with:
 - a) the provisions of Chapter 2M of the Corporations Act as they apply to Medibio; and
 - b) section 674 of the Corporations Act.
4. As at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act that is required to be set out in this notice under section 708AA(7) of the Corporations Act.
5. The potential effect that the issue of securities will have on the control of Medibio, and the consequences of that effect, will depend on a number of factors, including investor demand. To the extent that shareholders fail to take up their entitlements under the Offer, the percentage of holdings of those shareholders in Medibio may be diluted by those other shareholders who take up some, all or more than their entitlement. At this time, the issue of the securities under the Entitlement Offer is not expected to have a material effect or consequence on the control of Medibio given:
 - a) the Offer is structured as an partially underwritten pro-rata issue;
 - b) the current level of holdings of substantial holders (based on substantial holding notices that have been given to Medibio and lodged with ASX on or before the date of this notice); and
 - c) no participant in any shortfall will be offered Shares which would result in them holding more than 20% of the Shares on issue.

-ENDS-

Claude Solitario

Managing Director & CEO

Medibio Limited

For further information, please contact Mr Watkins on +61 3 9692 7222

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

Level 4, 100 Albert Road, South Melbourne, Vic 3205

Email: info@medibio.com.au | www.medibio.com.au

ACN: 008 130 336